Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Description

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Conditions

Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor, Locally Advanced Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Cincinnati

University of Cincinnati Medical Center, Cincinnati, Ohio, United States, 45219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Solid tumor malignancy with a clinical indication for radiation
  • * Patients must have measurable disease
  • * Target lesion(s) which are amenable to lattice therapy plan
  • * When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
  • * Age ≥18 years.
  • * ECOG Performance status ≤2
  • * Life expectancy greater than 3 months
  • * Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
  • * Ability to understand and the willingness to sign a written informed consent document
  • * Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
  • * Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
  • * Patients with a history of conditions which predispose them to increased radiation toxicity
  • * Patients with known contraindications to radiation therapy
  • * Patients with uncontrolled intercurrent illness
  • * Pregnant women

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Cincinnati,

Study Record Dates

2027-06-01